Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026)
Zoetis (ZTS) posted quarterly Non-Current Deferred Tax Liability of $130.0 million for Q1 2026, down 19.25% year-over-year from $161.0 million in Q1 2025, and down 5.11% quarter-over-quarter from $137.0 million in Q4 2025.
Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Non-Current Deferred Tax Liability for 15 consecutive years, with $130.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 19.25% year-over-year to $130.0 million; the TTM figure through Mar 2026 stood at $130.0 million (down 19.25% YoY), while the FY2025 annual figure was $137.0 million, down 17.96% from the prior year.
- Non-Current Deferred Tax Liability slipped to $130.0 million in Q1 2026 per ZTS's latest filing, from $137.0 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $287.0 million in Q1 2022 and bottomed at $121.0 million in Q2 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $170.5 million across 5 years, with a median of $156.0 million in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability slumped 55.84% — and 2024, when it soared 44.63%.
- Zoetis' Non-Current Deferred Tax Liability stood at $142.0 million in 2022, then gained by 2.82% to $146.0 million in 2023, then gained by 14.38% to $167.0 million in 2024, then dropped by 17.96% to $137.0 million in 2025, then declined by 5.11% to $130.0 million in 2026.
- Business Quant data shows ZTS's Non-Current Deferred Tax Liability at $130.0 million in Q1 2026, $137.0 million in Q4 2025, and $147.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.00 Mn |
| Jun 30, 2026 | 122.00 Mn |
| Mar 31, 2026 | 130.00 Mn |
| Mar 31, 2026 | 130.00 Mn |
| Dec 31, 2025 | 137.00 Mn |
| Dec 31, 2025 | 137.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Jun 30, 2025 | 156.00 Mn |
| Jun 30, 2025 | 156.00 Mn |
| Mar 31, 2025 | 161.00 Mn |
| Mar 31, 2025 | 161.00 Mn |
| Dec 31, 2024 | 167.00 Mn |
| Dec 31, 2024 | 167.00 Mn |
| Sep 30, 2024 | 172.00 Mn |
| Sep 30, 2024 | 172.00 Mn |
| Jun 30, 2024 | 175.00 Mn |
| Jun 30, 2024 | 175.00 Mn |
| Mar 31, 2024 | 136.00 Mn |
| Mar 31, 2024 | 136.00 Mn |